FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
|Articles|July 7, 2015
Kenneth Freundlich on Support for Patients With Hereditary Cancers
Author(s)Kenneth Freundlich
Kenneth Freundlich, neuropsychologist, Morris Psychological Group, Parsippany, NJ, and FORCE volunteer, comments on supporting patients with hereditary cancers.
Advertisement
Kenneth Freundlich, neuropsychologist, Morris Psychological Group, Parsippany, NJ, and FORCE volunteer, comments on supporting patients with hereditary cancers.
Advertisement
Related to this article
A phase 1 trial treated 15 patients with breast cancer that spread to the spinal fluid using a vaccine made from their own immune cells. One patient is now more than three years from diagnosis.
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Twenty-three years after a breast cancer diagnosis at 39, a survivor explains why her garage gym became a place to rebuild strength.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Advertisement
Advertisement